ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,316.00
0.01%
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs Yen
156.7275
0.00%
Brent Oil
79.395
0.00%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) ニュース

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VIRX
日付受信時刻ニュースソース見出しコード企業名
2024/06/0105 : 46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
2024/05/3008 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1805 : 05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1705 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1705 : 23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1505 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1420 : 00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1006 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
2024/05/1005 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
2024/05/1005 : 05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
2024/05/0805 : 05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
2024/04/1521 : 00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
2024/04/0121 : 30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
2024/03/0807 : 04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
2024/03/0806 : 19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
2024/03/0806 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
2024/03/0806 : 05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
2024/02/2922 : 00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
2024/02/2810 : 40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/02/2809 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/02/2809 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2024/02/1411 : 04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
2024/02/0706 : 05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
2024/01/0422 : 00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
2023/12/1222 : 00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
2023/12/0506 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2023/12/0422 : 30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
2023/11/2909 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2023/11/2909 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
2023/11/1807 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

最近閲覧した銘柄

NASDAQ
AMZN
Amazon.com
FX
USDGBP
US Dollar vs Sterling
NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
USOTC
BASFY
BASF (QX)
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
NYSE
NKE
Nike
SPI
SP500
S&P 500
AMEX
SPY
SPDR S&P 500
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有